Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Cybin is operational in Ireland, following its successful product launches and regulatory approvals in various global markets.

Cybin develops treatments for GAD and receives European authorities approval for a Phase 3 trial, which will enroll participants in Australia.

2 reports, 2 independent Updated Sep 2
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Cybin develops treatments for GAD and receives European authorities approval for a Phase 3 trial, which will enroll participants in Australia.

Who's involved

What this event is mainly about
CybinEurope

How it developed

Newest first. Tap a step to see who reported it.
  1. Cybin's CYB004 program is targeting the treatment of GAD.Sub-event
  2. Cybin secures European approval for Phase 3 GAD trials.1 source
  3. Cybin secured approvals in Ireland, Poland, and Greece for its multinational Phase 3 EMBRACE study.1 source

Keep exploring

Part of

Cybin is operational in Ireland, following its successful product launches and regulatory approvals in various global markets. All 1 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyCybin Inc. (CYBN) Launches Global Phase 3 Trial for Breakthrough Depression Therapy We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Cybin Inc. is one of them. Cybin In
  • Business WireCybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second study within the CYB003